This article is more than 5 years old. Information may no longer be current.

FDA gives nod to Prandin generic

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has granted tentative approval for the abbreviated new drug application for the generic version of Prandin, according to a press release.

Repaglinide (Prandin, Perrigo) belongs to the class of drugs known as meglitinides for the treatment of patients with type 2 diabetes. The brand name was first approved in 1997, and is currently available in 0.5-mg, 1-mg and 2-mg doses.